Navigation Links
ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Date:4/1/2008

FREDERICK, Md., April 1, 2008 /PRNewswire/ -- ImQuest BioSciences, Inc. announced today the publication of the results of an important structure- activity relationship study to investigate the efficacy and toxicity of a series of pyrimidinedione analogs against HIV-1 and HIV-2. The manuscript, published in the journal Antiviral Chemistry and Chemotherapy, shows the results of ImQuest's HIV drug development program based on compounds which it licensed from Samjin Pharmaceutical Co. Ltd. The report, authored by Robert W. Buckheit, Jr., Ph.D. (Executive Vice President and Chief Scientific Officer of ImQuest) describes the synthesis of the highly potent pyrimidinedione series and the structural features of the compounds which are responsible for their high level of potency against HIV, the expanded range of action to include HIV-2, and the unique dual mechanism of entry and RT inhibitory activity against HIV-1.

"The studies performed will allow us to focus our resources on the preclinical and clinical development of the most potent lead pyrimidinedione and to gain insight into the molecular features of the compounds which yield the high potency and characteristic dual mechanism of antiviral action of these unique compounds," explained Dr. Buckheit. Other coauthors on this paper include ImQuest virologists Tracy Hartman, Karen Watson and Lu Yang and Samjin chemists Ho-Seok Kwon, Sun-Hwan Lee, Jae-Woong Lee, Dong-Wook Kang, Sun-Gan Chung and Eui-Hwan Cho.

ImQuest expects to submit an IND to initiate Phase 1 human clinical trials with IQP-0410, a highly potent member of the pyrimidinedione series in the third quarter of 2008. In addition, ImQuest has initiated IND-enabling studies with the pyrimidinedione IQP-0528 as a potential anti-HIV topical microbicide.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in early stage drug development of novel compounds for the treatment of infectious disease and
'/>"/>

SOURCE ImQuest BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
5. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
6. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... N.J. , July 1, 2015  Echo ... device company focused on non-invasive continuous glucose monitoring ... its new and completely re-designed corporate website ... intuitive access to Echo,s technology and enhances the ... The new website better communicates to prospective customers ...
(Date:7/1/2015)... HEIGHTS, Utah , July 1, 2015 /PRNewswire/ ... ), a manufacturer and marketer of rehabilitation and ... completed its $4,025,000 private placement financing led by ... strategic private equity investor focused on the healthcare ... to promote organic growth and pursue potential strategic ...
(Date:7/1/2015)... , July 1, 2015 ExeGi Pharma, ... and probiotic treatments, announced today that it has been ... and Non-prescription Health Products Directorate (NNHPD) to sell Visbiome™ ... Visbiome was developed by Professor Claudio De Simone ... extensive clinical investigation. Professor De Simone recently signed an ...
Breaking Medicine Technology:Echo Therapeutics Announces New Website Launch 2Echo Therapeutics Announces New Website Launch 3Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 3ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3
... 2011 ImaginAb, Inc. and Eurogentec S.A. announce ... for producing engineered antibody fragments. The two companies ... high-performance Pichia pastoris expression system. Leveraging ... the collaboration will accelerate the development of ImaginAb,s ...
... Jan. 31, 2011 Global Real Estate Consultants has ... a new facility in Fremont. Global ... provide insight and transparency in the Fremont commercial real ... Inc,s 350,000 sq. ft. state-of-the-art manufacturing facility with pilot ...
Cached Medicine Technology:ImaginAb, Inc. and Eurogentec S.A. Collaborate to Produce Antibody Fragments in Pichia 2Boehringer Ingelheim to Purchase Amgen's Fremont (USA) Facility 2
(Date:7/1/2015)... ... ... Incentivizing the use of generic drugs has been an easy way for plans ... off the prices for the brand-name products. But now that generics are experiencing record ... these high-cost generic drugs. The July issue of Atlantic Information Services, Inc.’s (AIS) The ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Recovery Workforce Summit: 2015 PRA Annual ... editor of The Atlantic, as a keynote on June 2nd in Philadelphia, PA. Stossel ... his personal story added power and reach to the essential message, while opening doors ...
(Date:7/1/2015)... ... 01, 2015 , ... The executive team from Nutritional Products ... number of nutritional and beauty products, announced the company was successful in forging ... Sports Nutrition conference in Tampa, Florida. This specific ECRM trade show gives companies ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The Thule ... case was relentlessly tested to ensure it lived up to Thule’s rigorous standards. Due ... the protection and quality Thule owners have come to expect. , The ...
(Date:7/1/2015)... ... 2015 , ... AvePoint, the established leader in ... new operational office in Zurich, Switzerland. The new facility will deliver enterprise-level Microsoft ... for organizations throughout the Swiss market. , “AvePoint is committed to addressing ...
Breaking Medicine News(10 mins):Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 2Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 3Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 2Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 3Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 4Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 5Health News:NPI Executives Report Great Success at ECRM Conference 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 3
... a common cause of death among patients with pneumonia, sepsis ... The damage often occurs suddenly and can cause life-threatening breathing ... treatments. Patients usually are put on ventilators to give their ... doctors can do but wait and hope for the best. ...
... surface, a team of researchers from the University of ... Korean institutions have identified two distinct neuronal signaling pathways ... variety of skin diseases. One pathway produces the therapeutic ... effect. The findings, published in this week,s early ...
... at the University of Utah,s Comprehensive Arrhythmia and Research ... imaging (DE-MRI) holds promise for predicting the risks of ... U.S. Their latest study on a novel application of ... the Journal of the American College of Cardiology ...
... TUESDAY, Feb. 8 (HealthDay News) -- Teens who are already popular ... to bully other kids, new research suggests. The kids seem ... the eyes of their peers, according to the study, published in ... Researchers asked about 3,700 students in 8th, 9th and 10th grades ...
... of health inequalities between socio-economic groups has been noticed ... Organization, the World Bank and the United Nations Development ... importance and made this issue a priority. There is ... but have a particular impact on mental health. A ...
... This release is available in Spanish . ... the Spanish Higher Institute for Scientific Research (CSIC) have ... extensively employed in the development of cosmetic and drug ... of nanotechnology. Phospholipid vesicles (liposomes) are colloidal systems ...
Cached Medicine News:Health News:Gene protects lung from damage due to pneumonia, sepsis, trauma, transplants 2Health News:Gene protects lung from damage due to pneumonia, sepsis, trauma, transplants 3Health News:The hitch in the drug? The itch in the drug 2Health News:Study shows delayed-enhancement MRI may predict, prevent strokes 2Health News:Bullying May Accompany Drive to Be Popular 2Health News:Bullying May Accompany Drive to Be Popular 3Health News:Income inequalities are increasing the occurence of depression during financial crisis 2Health News:New data obtained on liposomes employed in drug encapsulation and gene therapies 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: